Pfizer (PFE) Moves Forward With Once-Daily Obesity Pill Study

Pfizer (PFE) announced that it has selected its preferred once-daily modified-release formulation of danuglipron, its oral GLP-1 receptor agonist, for further development as a weight loss pill based on encouraging results from an ongoing study. It evaluated several formulations of danuglipron and said that one showed “the most favorable profile.” Pfizer, however, did not announce any detailed clinical data from the study.In the second half of the year, Pfizer will conduct dose optimization studies on multip ...